GNMSF (Genmab AS) Research & Development: $1,687 Mil (TTM As of Mar. 2026)


GNMSF Genmab AS GNMSF
95 GF Score
Price $257.44
GF Value $343.48
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Genmab AS Research & Development?

Genmab AS GNMSF 95 Research & Development is $1,687 Mil as of Mar. 2026. GuruFocus rates GNMSF with a GF Score™ of 95/100 and a GF Value™ of $343.48 (Modestly Undervalued). The stock has 5 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Genmab AS's Research & Development for the three months ended in Mar. 2026 was $440 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was $1,687 Mil.

Genmab AS  (OTCPK:GNMSF) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Genmab AS Research & Development Related Terms

Genmab AS Research & Development Historical Data

* Premium members only.

The historical data trend for Genmab AS's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genmab AS Research & Development Chart

Genmab AS Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 636.50 800.53 1,107.00 1,414.00 1,606.00

Genmab AS Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 359.00 364.00 357.00 526.00 440.00
GNMSF
95GF Score
Genmab AS GNMSF
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Genmab AS Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1,687 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $1,687 Mil mean?
Genmab AS (GNMSF) has a Research & Development of $1,687 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Genmab AS and its competitors.
Is Genmab AS's Research & Development too high?
Genmab AS's current Research & Development is $1,687 Mil. Overall, Genmab AS has a GF Score™ of 95/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genmab AS's Research & Development compare to VRTX and REGN?
Genmab AS's Research & Development of $1,687 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Genmab AS and its competitors. Genmab AS's current Research & Development is $1,687 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genmab AS stock overvalued right now?
Based on GuruFocus' analysis, Genmab AS (GNMSF) is currently considered Modestly Undervalued. The stock's GF Value™ is $343.48, compared to a current price of $257.44 — trading 25.1% below its estimated fair value. The current Research & Development is $1,687 Mil. Genmab AS's overall GF Score™ is 95/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Genmab AS (GNMSF), the current Research & Development is $1,687 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Genmab AS (GNMSF) Overvalued in 2026?

Based on GuruFocus' analysis, Genmab AS stock appears to be undervalued. The current stock price of $257.44 is trading 25.1% below its estimated GF Value™ of $343.48. GuruFocus considers Genmab AS to be Modestly Undervalued.

Key valuation signals for GNMSF:

  • Research & Development: $1,687 Mil
  • GF Value™: $343.48 vs. price of $257.44 (25.1% below fair value)
  • GF Score™: 95/100 with 5 warning signs

No single metric tells the full story. See the GNMSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Genmab AS Business Description

Address Carl Jacobsens Vej 30, Valby, DNK, 2500
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
95GF Score

Get the complete analysis for GNMSF

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$257.44
Price
$343.48
GF Value